Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials

BACKGROUND: We sought to examine the efficacy and safety of 2 PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors: alirocumab and evolocumab. METHODS AND RESULTS: We performed a systematic review and meta‐analysis of randomized controlled trials comparing treatment with and without PCSK...

Descripción completa

Detalles Bibliográficos
Autores principales: Karatasakis, Aris, Danek, Barbara A, Karacsonyi, Judit, Rangan, Bavana V, Roesle, Michele K, Knickelbine, Thomas, Miedema, Michael D, Khalili, Houman, Ahmad, Zahid, Abdullah, Shuaib, Banerjee, Subhash, Brilakis, Emmanouil S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Systematic Review and Meta‐Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779013/
https://www.ncbi.nlm.nih.gov/pubmed/29223954
http://dx.doi.org/10.1161/JAHA.117.006910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779013/
https://www.ncbi.nlm.nih.gov/pubmed/29223954
http://dx.doi.org/10.1161/JAHA.117.006910

Ejemplares similares